{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:23:08Z","timestamp":1790007788872,"version":"4.0.1"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"DOI":"10.1007\/s11904-026-00778-z","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T07:09:24Z","timestamp":1773990564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of Timing and Duration of ART on the Composition of HIV Reservoirs: Implications for HIV Cure Strategies"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6924-2222","authenticated-orcid":false,"given":"Sukeshani","family":"Salwe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0791-2128","authenticated-orcid":false,"given":"Ashwini","family":"Shete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"778_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1478703","volume":"15","author":"C Nel","year":"2024","unstructured":"Nel C, Frater J. Enhancing broadly neutralising antibody suppression of HIV by immune modulation and vaccination. Front Immunol. 2024;15:1478703.","journal-title":"Front Immunol"},{"key":"778_CR2","doi-asserted-by":"crossref","unstructured":"Chun TW et al. Nov., Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy., Proc. Natl. Acad. Sci. U. S. A., vol. 94, no. 24, pp. 13193\u201313197, 1997.","DOI":"10.1073\/pnas.94.24.13193"},{"key":"778_CR3","doi-asserted-by":"crossref","unstructured":"Ananworanich J, Dub\u00e9 K, Chomont N. How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs? Curr Opin HIV AIDS. Jan. 2015;10(1):18\u201328.","DOI":"10.1097\/COH.0000000000000122"},{"key":"778_CR4","doi-asserted-by":"crossref","unstructured":"Kinloch NN et al. Dec., HIV reservoirs are dominated by genetically younger and clonally enriched proviruses., MBio, vol. 14, no. 6, p. e0241723, 2023.","DOI":"10.1128\/mbio.02417-23"},{"issue":"1","key":"778_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12977-018-0448-8","volume":"15","author":"EM Anderson","year":"2018","unstructured":"Anderson EM, Maldarelli F. The role of integration and clonal expansion in HIV infection: live long and prosper Ben Berkhout, Alexander Pasternak. Retrovirology. 2018;15(1):1\u201322.","journal-title":"Retrovirology"},{"key":"778_CR6","doi-asserted-by":"crossref","unstructured":"Kimata JT, Rice AP, Wang J. Challenges and strategies for the eradication of the HIV reservoir. Curr Opin Immunol. Oct. 2016;42:65\u201370.","DOI":"10.1016\/j.coi.2016.05.015"},{"issue":"9","key":"778_CR7","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1089\/aid.2018.0105","volume":"34","author":"LM Agosto","year":"2018","unstructured":"Agosto LM, Henderson AJ. CD4(+) T cell subsets and pathways to HIV latency. AIDS Res Hum Retroviruses. 2018;34(9):780\u20139.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"39","key":"778_CR8","doi-asserted-by":"publisher","first-page":"16934","DOI":"10.1073\/pnas.1002894107","volume":"107","author":"PU Cameron","year":"2010","unstructured":"Cameron PU, et al. Establishment of HIV-1 latency in resting CD4\u2009+\u2009T cells depends on chemokine-induced changes in the actin cytoskeleton. Proc Natl Acad Sci U S A. 2010;107(39):16934\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"778_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S2055-6640(20)30490-8","volume":"1","author":"DA Kulpa","year":"2015","unstructured":"Kulpa DA, Chomont N. HIV persistence in the setting of antiretroviral therapy: when, where and how does HIV hide? J Virus Erad. 2015;1:59\u201366.","journal-title":"J Virus Erad"},{"issue":"1","key":"778_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2055-6640(20)31149-3","volume":"1","author":"L Micci","year":"2015","unstructured":"Micci L, McGary CS, Paiardini M. Animal models in HIV cure research. J Virus Erad. 2015;1(1):17\u201322.","journal-title":"J Virus Erad"},{"key":"778_CR11","doi-asserted-by":"crossref","unstructured":"Kumar N, Chahroudi A, Silvestri G. Animal models to achieve an HIV cure. Curr Opin HIV AIDS. Jul. 2016;11(4):432\u201341.","DOI":"10.1097\/COH.0000000000000290"},{"issue":"3","key":"778_CR12","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2013.09.020","volume":"155","author":"YC Ho","year":"2013","unstructured":"Ho YC, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell. 2013;155(3):540.","journal-title":"Cell"},{"issue":"9","key":"778_CR13","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.4156","volume":"22","author":"KM Bruner","year":"2016","unstructured":"Bruner KM, et al. Defective proviruses rapidly accumulate during acute HIV-1 infection. Nat Med. 2016;22(9):1043\u20139.","journal-title":"Nat Med"},{"key":"778_CR14","doi-asserted-by":"crossref","unstructured":"Simonetti FR et al. Feb., Clonally expanded CD4\u2009+\u2009T cells can produce infectious HIV-1 in vivo., Proc. Natl. Acad. Sci. U. S. A., vol. 113, no. 7, pp. 1883\u20131888, 2016.","DOI":"10.1073\/pnas.1522675113"},{"key":"778_CR15","doi-asserted-by":"crossref","unstructured":"Lee GQ et al. Jun., Clonal expansion of genome-intact HIV-1 in functionally polarized Th1 CD4\u2009+\u2009T cells., J. Clin. Invest., vol. 127, no. 7, pp. 2689\u20132696, 2017.","DOI":"10.1172\/JCI93289"},{"key":"778_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw5589","author":"M-R Abrahams","year":"2019","unstructured":"Abrahams M-R, et al. The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation. Sci Transl Med. 2019. https:\/\/doi.org\/10.1126\/scitranslmed.aaw5589.","journal-title":"Sci Transl Med"},{"key":"778_CR17","doi-asserted-by":"crossref","unstructured":"Einkauf KB et al. Parallel analysis of transcription, integration, and sequence of single HIV-1 proviruses. Cell, 185, 2, pp. 266\u201382.e15, Jan. 2022.","DOI":"10.1016\/j.cell.2021.12.011"},{"key":"778_CR18","doi-asserted-by":"crossref","unstructured":"Reddy K et al. Differences in HIV-1 reservoir size, landscape characteristics and decay dynamics in acute and chronic treated HIV-1 Clade C infection, medRxiv, p. 2024.02.16.24302713, Jan. 2024.","DOI":"10.1101\/2024.02.16.24302713"},{"key":"778_CR19","doi-asserted-by":"crossref","unstructured":"Brodin J et al. Nov., Establishment and stability of the latent HIV-1 DNA reservoir., Elife, vol. 5, 2016.","DOI":"10.7554\/eLife.18889"},{"issue":"5","key":"778_CR20","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.02053-23","volume":"14","author":"N Ikeogu","year":"2023","unstructured":"Ikeogu N, Ajibola O, Zayats R, Murooka TT. Identifying physiological tissue niches that support the HIV reservoir in T cells. MBio. 2023;14(5):e0205323.","journal-title":"MBio"},{"issue":"6","key":"778_CR21","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/mi.2008.35","volume":"1","author":"M Macal","year":"2008","unstructured":"Macal M, et al. Effective CD4\u2009+\u2009T-cell restoration in gut-associated lymphoid tissue of HIV-infected patients is associated with enhanced Th17 cells and polyfunctional HIV-specific T-cell responses. Mucosal Immunol. 2008;1(6):475\u201388.","journal-title":"Mucosal Immunol"},{"key":"778_CR22","doi-asserted-by":"crossref","unstructured":"Guadalupe M et al. Nov., Severe CD4\u2009+\u2009T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy., J. Virol., vol. 77, no. 21, pp. 11708\u201311717, 2003.","DOI":"10.1128\/JVI.77.21.11708-11717.2003"},{"key":"778_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2019.00362","volume":"9","author":"C Wallet","year":"2019","unstructured":"Wallet C, et al. Microglial cells: the main HIV-1 reservoir in the brain. Front Cell Infect Microbiol. 2019;9:362.","journal-title":"Front Cell Infect Microbiol"},{"key":"778_CR24","doi-asserted-by":"crossref","unstructured":"Tang Y et al. Jun., Brain microglia serve as a persistent HIV reservoir despite durable antiretroviral therapy., J. Clin. Invest., vol. 133, no. 12, 2023.","DOI":"10.1172\/JCI167417"},{"key":"778_CR25","doi-asserted-by":"crossref","unstructured":"N\u00fchn MM et al. Mar., Microglia Exhibit a Unique Intact HIV Reservoir in Human Postmortem Brain Tissue., Viruses, vol. 17, no. 4, 2025.","DOI":"10.3390\/v17040467"},{"key":"778_CR26","doi-asserted-by":"crossref","unstructured":"Banga R, Perreau M. The multifaceted nature of HIV tissue reservoirs. Curr Opin HIV AIDS. May 2024;19(3):116\u201323.","DOI":"10.1097\/COH.0000000000000851"},{"key":"778_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/v13122512","author":"C-Y Lau","year":"2021","unstructured":"Lau C-Y, Adan MA, Maldarelli F. Why the HIV reservoir never runs dry: clonal expansion and the characteristics of HIV-infected cells challenge strategies to cure and control HIV infection. Viruses. 2021. https:\/\/doi.org\/10.3390\/v13122512.","journal-title":"Viruses"},{"issue":"48","key":"778_CR28","doi-asserted-by":"publisher","first-page":"E11341","DOI":"10.1073\/pnas.1813512115","volume":"115","author":"C-L Lu","year":"2018","unstructured":"Lu C-L, et al. Relationship between intact HIV-1 proviruses in circulating CD4\u2009+\u2009T cells and rebound viruses emerging during treatment interruption. Proc Natl Acad Sci U S A. 2018;115(48):E11341\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"778_CR29","doi-asserted-by":"crossref","unstructured":"Tyers L et al. Jan., HIV-1 Rebound Virus Consists of a Small Number of Lineages That Entered the Reservoir Close to ART Initiation., bioRxiv Prepr. Serv. Biol., 2025.","DOI":"10.1101\/2025.01.29.635391"},{"key":"778_CR30","doi-asserted-by":"crossref","unstructured":"Chen J et al. The reservoir of latent HIV. Front Cell Infect Microbiol, vol. 12, 2022.","DOI":"10.3389\/fcimb.2022.945956"},{"key":"778_CR31","doi-asserted-by":"crossref","unstructured":"Massanella M, et al. Long-term effects of early antiretroviral initiation on HIV reservoir markers: a longitudinal analysis of the MERLIN clinical study. Lancet Microbe. May 2021;2(5):e198\u2013209.","DOI":"10.1016\/S2666-5247(21)00010-0"},{"key":"778_CR32","doi-asserted-by":"crossref","unstructured":"Leyre L, et al. Abundant HIV-infected cells in blood and tissues are rapidly cleared upon ART initiation during acute HIV infection. Sci Transl Med. Mar. 2020;12(533):eaav3491.","DOI":"10.1126\/scitranslmed.aav3491"},{"key":"778_CR33","unstructured":"Ch\u00e9ret A et al. Jul., Combined ART started during acute HIV infection protects central memory CD4\u2009+\u2009T cells and can induce remission, J. Antimicrob. Chemother., vol. 70, no. 7, pp. 2108\u20132120, 2015."},{"issue":"1","key":"778_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07881-9","volume":"9","author":"JB Whitney","year":"2018","unstructured":"Whitney JB, et al. Prevention of SIVmac251 reservoir seeding in rhesus monkeys by early antiretroviral therapy. Nat Commun. 2018;9(1):5429.","journal-title":"Nat Commun"},{"key":"778_CR35","doi-asserted-by":"crossref","unstructured":"Chomont N et al. Aug., HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation., Nat. Med., vol. 15, no. 8, pp. 893\u2013900, 2009.","DOI":"10.1038\/nm.1972"},{"key":"778_CR36","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.132997","author":"MJ Peluso","year":"2020","unstructured":"Peluso MJ, et al. Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy. JCI Insight. 2020. https:\/\/doi.org\/10.1172\/jci.insight.132997.","journal-title":"JCI Insight"},{"key":"778_CR37","doi-asserted-by":"crossref","unstructured":"Vela LC et al. Nov., Profound reduction of HIV-1 reservoir cells over 3 decades of antiretroviral therapy started in early infancy., JCI insight, vol. 10, no. 1, 2024.","DOI":"10.1172\/jci.insight.186550"},{"key":"778_CR38","doi-asserted-by":"crossref","unstructured":"Deng K, et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature. Jan. 2015;517(7534):381\u20135.","DOI":"10.1038\/nature14053"},{"key":"778_CR39","doi-asserted-by":"crossref","unstructured":"Sedaghat AR, Siliciano JD, Brennan TP, Wilke CO, Siliciano RF. Limits on Replenishment of the Resting CD4\u2009+\u2009T Cell Reservoir for HIV in Patients on HAART. PLOS Pathog. Aug. 2007;3(8):e122.","DOI":"10.1371\/journal.ppat.0030122"},{"key":"778_CR40","doi-asserted-by":"crossref","unstructured":"Hong FF, Mellors JW. Changes in HIV reservoirs during long-term antiretroviral therapy. Curr Opin HIV AIDS. Jan. 2015;10(1):43\u20138.","DOI":"10.1097\/COH.0000000000000119"},{"key":"778_CR41","doi-asserted-by":"crossref","unstructured":"Yeh Y-HJ, Yang K, Razmi A, Ho Y-C. The Clonal Expansion Dynamics of the HIV-1 Reservoir: Mechanisms of Integration Site-Dependent Proliferation and HIV-1 Persistence., Viruses, vol. 13, no. 9, Sep. 2021.","DOI":"10.3390\/v13091858"},{"key":"778_CR42","doi-asserted-by":"crossref","unstructured":"Sengupta S, Siliciano RF. Targeting the Latent Reservoir for HIV-1. Immunity. May 2018;48(5):872\u201395.","DOI":"10.1016\/j.immuni.2018.04.030"},{"key":"778_CR43","unstructured":"Fidler S et al. Mar., Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial., Lancet (London, England), vol. 395, no. 10227, pp. 888\u2013898, 2020."},{"issue":"18","key":"778_CR44","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1007\/s00018-019-03156-8","volume":"76","author":"I Sadowski","year":"2019","unstructured":"Sadowski I, Hashemi FB. Strategies to eradicate HIV from infected patients: elimination of latent provirus reservoirs. Cell Mol Life Sci. 2019;76(18):3583\u2013600.","journal-title":"Cell Mol Life Sci"},{"key":"778_CR45","doi-asserted-by":"crossref","unstructured":"Gruell H, et al. Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial. Lancet Microbe. Mar. 2022;3(3):e203\u201314.","DOI":"10.1016\/S2666-5247(21)00239-1"},{"issue":"3","key":"778_CR46","first-page":"668","volume":"1","author":"G Mousseau","year":"2012","unstructured":"Mousseau G, Valente S. Strategies to block HIV transcription: focus on small molecule Tat inhibitors. Biology (Basel). 2012;1(3):668\u201397.","journal-title":"Biology (Basel)"},{"key":"778_CR47","doi-asserted-by":"crossref","unstructured":"Mousseau G, Kessing CF, Fromentin R, Trautmann L, Chomont N, Valente ST. The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency. MBio. Jul. 2015;6(4):e00465.","DOI":"10.1128\/mBio.00465-15"},{"issue":"4","key":"778_CR48","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.3390\/v6041715","volume":"6","author":"A Battistini","year":"2014","unstructured":"Battistini A, Sgarbanti M. HIV-1 latency: an update of molecular mechanisms and therapeutic strategies. Viruses. 2014;6(4):1715\u201358.","journal-title":"Viruses"},{"key":"778_CR49","doi-asserted-by":"crossref","unstructured":"Wang G, Zhao N, Berkhout B, Das AT. CRISPR-Cas based antiviral strategies against HIV-1. Virus Res. Jan. 2018;244:321\u201332.","DOI":"10.1016\/j.virusres.2017.07.020"},{"key":"778_CR50","doi-asserted-by":"crossref","unstructured":"Qu X et al. Sep., Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells., Nucleic Acids Res., vol. 41, no. 16, pp. 7771\u20137782, 2013.","DOI":"10.1093\/nar\/gkt571"},{"key":"778_CR51","doi-asserted-by":"crossref","unstructured":"Yin C, et al. Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models. Mol Ther. May 2017;25(5):1168\u201386.","DOI":"10.1016\/j.ymthe.2017.03.012"},{"key":"778_CR52","doi-asserted-by":"crossref","unstructured":"Qu X et al. Sep., Zinc finger nuclease: a new approach for excising HIV-1 proviral DNA from infected human T cells., Mol. Biol. Rep., vol. 41, no. 9, pp. 5819\u20135827, 2014.","DOI":"10.1007\/s11033-014-3456-3"},{"key":"778_CR53","unstructured":"Pablo T, et al. Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV. N Engl J Med. May 2025;370(10):901\u201310."},{"issue":"7","key":"778_CR54","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMoa0802905","volume":"360","author":"G H\u00fctter","year":"2009","unstructured":"H\u00fctter G, et al. Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation. N Engl J Med. 2009;360(7):692\u20138.","journal-title":"N Engl J Med"},{"key":"778_CR55","doi-asserted-by":"crossref","unstructured":"Xu L et al. Sep., CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia., N. Engl. J. Med., vol. 381, no. 13, pp. 1240\u20131247, 2019.","DOI":"10.1056\/NEJMoa1817426"},{"key":"778_CR56","doi-asserted-by":"crossref","unstructured":"Zhen A, et al. Long-term persistence and function of hematopoietic stem cell-derived chimeric antigen receptor T cells in a nonhuman primate model of HIV\/AIDS. PLoS Pathog. Dec. 2017;13(12):e1006753.","DOI":"10.1371\/journal.ppat.1006753"},{"key":"778_CR57","doi-asserted-by":"crossref","unstructured":"Lu C-L et al. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science, 352, 6288, pp. 1001\u20134, May 2016.","DOI":"10.1126\/science.aaf1279"},{"issue":"2","key":"778_CR58","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nm.4268","volume":"23","author":"M Caskey","year":"2017","unstructured":"Caskey M, et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat Med. 2017;23(2):185\u201391.","journal-title":"Nat Med"},{"issue":"7724","key":"778_CR59","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","volume":"561","author":"P Mendoza","year":"2018","unstructured":"Mendoza P, et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature. 2018;561(7724):479\u201384.","journal-title":"Nature"},{"key":"778_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.663919","volume":"12","author":"P Suryawanshi","year":"2021","unstructured":"Suryawanshi P, Bagul R, Shete A, Thakar M. Anti-HIV-1 ADCC and HIV-1 Env can be partners in reducing latent HIV reservoir. Front Immunol. 2021;12:663919.","journal-title":"Front Immunol"},{"key":"778_CR61","doi-asserted-by":"crossref","unstructured":"Yates NL et al. Mar., Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination., Sci. Transl. Med., vol. 6, no. 228, p. 228ra39, 2014.","DOI":"10.1126\/scitranslmed.3007730"},{"key":"778_CR62","doi-asserted-by":"crossref","unstructured":"Madhavi V et al. Feb., Antibody-dependent effector functions against HIV decline in subjects receiving antiretroviral therapy., J. Infect. Dis., vol. 211, no. 4, pp. 529\u2013538, 2015.","DOI":"10.1093\/infdis\/jiu486"},{"key":"778_CR63","doi-asserted-by":"crossref","unstructured":"Ackerman ME et al. Mar., A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples., J. Immunol. Methods, vol. 366, no. 1\u20132, pp. 8\u201319, 2011.","DOI":"10.1016\/j.jim.2010.12.016"},{"key":"778_CR64","doi-asserted-by":"crossref","unstructured":"Walker-Sperling VE, Pohlmeyer CW, Tarwater PM, Blankson JN. The Effect of Latency Reversal Agents on Primary CD8\u2009+\u2009T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication. EBioMedicine. Jun. 2016;8:217\u201329.","DOI":"10.1016\/j.ebiom.2016.04.019"},{"issue":"7475","key":"778_CR65","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/nature12744","volume":"503","author":"DH Barouch","year":"2013","unstructured":"Barouch DH, et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature. 2013;503(7475):224\u20138.","journal-title":"Nature"},{"key":"778_CR66","doi-asserted-by":"publisher","first-page":"103840","DOI":"10.1016\/j.ebiom.2022.103840","volume":"76","author":"C Gubser","year":"2022","unstructured":"Gubser C, Chiu C, Lewin SR, Rasmussen TA. Immune checkpoint blockade in HIV. EBioMedicine. 2022;76:103840.","journal-title":"EBioMedicine"},{"key":"778_CR67","doi-asserted-by":"crossref","unstructured":"Shete A, Suryawanshi P, Godbole S, Pawar J, Paranjape R, Thakar M. HIV-infected CD4\u2009+\u2009T Cells Use T-bet-dependent Pathway for Production of IL-10 Upon Antigen Recognition. Scand J Immunol. Apr. 2016;83(4):288\u201396.","DOI":"10.1111\/sji.12422"},{"key":"778_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2020.101412","volume":"51","author":"AR Ward","year":"2021","unstructured":"Ward AR, Mota TM, Jones RB. Immunological approaches to HIV cure. Semin Immunol. 2021;51:101412.","journal-title":"Semin Immunol"},{"key":"778_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02339","volume":"9","author":"Z Boyer","year":"2018","unstructured":"Boyer Z, Palmer S. Targeting immune checkpoint molecules to eliminate latent HIV. Front Immunol. 2018;9:2339.","journal-title":"Front Immunol"},{"key":"778_CR70","doi-asserted-by":"crossref","unstructured":"Spragg C, De Silva Feelixge H, Jerome KR. Cell and gene therapy strategies to eradicate HIV reservoirs. Curr Opin HIV AIDS. Jul. 2016;11(4):442\u20139.","DOI":"10.1097\/COH.0000000000000284"},{"issue":"10","key":"778_CR71","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1097\/QAD.0b013e3282fd6df4","volume":"22","author":"NM Archin","year":"2008","unstructured":"Archin NM, et al. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4\u2009+\u2009T cells. AIDS. 2008;22(10):1131\u20135.","journal-title":"AIDS"},{"key":"778_CR72","doi-asserted-by":"crossref","unstructured":"Elliott JH et al. Oct., Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy., PLoS Pathog., vol. 10, no. 10, p. e1004473, 2014.","DOI":"10.1371\/journal.ppat.1004473"},{"key":"778_CR73","doi-asserted-by":"crossref","unstructured":"Archin NM, et al. Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency. J Clin Invest. Aug. 2017;127(8):3126\u201335.","DOI":"10.1172\/JCI92684"},{"issue":"12","key":"778_CR74","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1038\/s41591-024-03247-5","volume":"30","author":"B Julg","year":"2024","unstructured":"Julg B, et al. Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1\/2a trial. Nat Med. 2024;30(12):3534\u201343.","journal-title":"Nat Med"},{"issue":"6","key":"778_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jia2.26495","volume":"28","author":"S Karuna","year":"2025","unstructured":"Karuna S, et al. Analytical treatment interruption among women with HIV in southern Africa who received VRC01 or placebo in the Antibody Mediated Prevention Study: ATI stakeholder engagement, implementation and early clinical data. J Int AIDS Soc. 2025;28(6):1\u201315.","journal-title":"J Int AIDS Soc"},{"issue":"4","key":"778_CR76","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1468-1293.2012.01040.x","volume":"14","author":"O Gasser","year":"2013","unstructured":"Gasser O, et al. Expansion of interferon-\u03b3-secreting HIV-specific T cells during successful antiretroviral therapy. HIV Med. 2013;14(4):241\u20136.","journal-title":"HIV Med"},{"issue":"1","key":"778_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41421-024-00658-z","volume":"10","author":"Y Mao","year":"2024","unstructured":"Mao Y, et al. Efficacy and safety of novel multifunctional M10 CAR-T cells in HIV-1-infected patients: a phase I, multicenter, single-arm, open-label study. Cell Discov. 2024;10(1):1\u201316.","journal-title":"Cell Discov"},{"key":"778_CR78","doi-asserted-by":"crossref","unstructured":"S\u00e1ez-Ciri\u00f3n A et al. Mar., Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study., PLoS Pathog., vol. 9, no. 3, p. e1003211, 2013.","DOI":"10.1371\/journal.ppat.1003211"},{"key":"778_CR79","doi-asserted-by":"crossref","unstructured":"Routy J-P, Mehraj V, Cao W. HIV immunotherapy comes of age: implications for prevention, treatment and cure., Expert review of clinical immunology, vol. 12, no. 2. England, pp. 91\u201394, 2016.","DOI":"10.1586\/1744666X.2016.1112269"},{"key":"778_CR80","doi-asserted-by":"crossref","unstructured":"Okoye AA et al. Sep., Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound., Nat. Med., vol. 24, no. 9, pp. 1430\u20131440, 2018.","DOI":"10.1038\/s41591-018-0130-7"},{"issue":"7731","key":"778_CR81","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41586-018-0600-6","volume":"563","author":"EN Borducchi","year":"2018","unstructured":"Borducchi EN, et al. Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature. 2018;563(7731):360\u20134.","journal-title":"Nature"},{"key":"778_CR82","doi-asserted-by":"crossref","unstructured":"Li JZ et al. Mar., Time to Viral Rebound After Interruption of Modern Antiretroviral Therapies., Clin. Infect. Dis. an Off. Publ. Infect. Dis. Soc. Am., vol. 74, no. 5, pp. 865\u2013870, 2022.","DOI":"10.1093\/cid\/ciab541"},{"issue":"7","key":"778_CR83","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/infdis\/jiad292","volume":"228","author":"L J\u00f6rimann","year":"2023","unstructured":"J\u00f6rimann L, et al. Absence of proviral human immunodeficiency virus (HIV) type 1 evolution in early-treated individuals with HIV switching to dolutegravir monotherapy during 48 weeks. J Infect Dis. 2023;228(7):907\u201318.","journal-title":"J Infect Dis"},{"key":"778_CR84","doi-asserted-by":"crossref","unstructured":"Whitney JB et al. Aug., Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys., Nature, vol. 512, no. 7512, pp. 74\u201377, 2014.","DOI":"10.1038\/nature13594"},{"key":"778_CR85","doi-asserted-by":"crossref","unstructured":"Maldarelli F et al. Jul., HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells., Science, vol. 345, no. 6193, pp. 179\u2013183, 2014.","DOI":"10.1126\/science.1254194"},{"key":"778_CR86","doi-asserted-by":"crossref","unstructured":"Cohn LB et al. Jan., HIV-1 integration landscape during latent and active infection., Cell, vol. 160, no. 3, pp. 420\u2013432, 2015.","DOI":"10.1016\/j.cell.2015.01.020"},{"key":"778_CR87","doi-asserted-by":"crossref","unstructured":"Rasmussen TA, Lewin SR. Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents? Curr Opin HIV AIDS. Jul. 2016;11(4):394\u2013401.","DOI":"10.1097\/COH.0000000000000279"},{"key":"778_CR88","doi-asserted-by":"crossref","unstructured":"Ling L et al. Analysis of the effect of HDAC inhibitors on the formation of the HIV reservoir. MBio, 15, 9, 2024.","DOI":"10.1128\/mbio.01632-24"},{"issue":"3","key":"778_CR89","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1093\/infdis\/jiad423","volume":"229","author":"CL Gay","year":"2024","unstructured":"Gay CL, et al. The effects of human immunodeficiency virus type 1 (HIV-1) antigen-expanded specific T-cell therapy and vorinostat on persistent HIV-1 infection in people with HIV on antiretroviral therapy. J Infect Dis. 2024;229(3):743\u201352.","journal-title":"J Infect Dis"},{"issue":"7","key":"778_CR90","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1097\/QAD.0000000000000178","volume":"28","author":"J Ananworanich","year":"2014","unstructured":"Ananworanich J, et al. Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children. AIDS. 2014;28(7):1015\u201320.","journal-title":"AIDS"},{"key":"778_CR91","doi-asserted-by":"publisher","first-page":"RP96617","DOI":"10.7554\/eLife.96617.4","volume":"13","author":"K Reddy","year":"2025","unstructured":"Reddy K, et al. Differences in HIV-1 reservoir size, landscape characteristics, and decay dynamics in acute and chronic treated HIV-1 clade C infection. Elife. 2025;13:RP96617.","journal-title":"Elife"},{"issue":"1","key":"778_CR92","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.chom.2017.12.004","volume":"23","author":"Y Kim","year":"2018","unstructured":"Kim Y, Anderson JL, Lewin SR. Getting the \u2018kill\u2019 into \u2018shock and kill\u2019: strategies to eliminate latent HIV. Cell Host Microbe. 2018;23(1):14\u201326.","journal-title":"Cell Host Microbe"},{"key":"778_CR93","doi-asserted-by":"crossref","unstructured":"Li JZ et al. Feb., Predictors of HIV rebound differ by timing of antiretroviral therapy initiation., JCI insight, vol. 9, no. 3, 2024.","DOI":"10.1172\/jci.insight.173864"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-026-00778-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11904-026-00778-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-026-00778-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T07:09:35Z","timestamp":1773990575000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11904-026-00778-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":93,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["778"],"URL":"https:\/\/doi.org\/10.1007\/s11904-026-00778-z","relation":{},"ISSN":["1548-3576"],"issn-type":[{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"7"}}